Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Last trade$1.79
Day change+$0.035 (+2.00%)
Day range$1.72 – $1.81
Volume1,311,925
Market cap$779M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$779.16M
Price / earnings
—
Price / book
4.76×
Price / sales
20.3×
EV / sales
20.5×
EV / EBITDA
-13.54×
Profitability
Earnings per share
-$0.14
Return on assets
-25.76%
Return on equity
-38.06%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.32×
Current ratio
10.63×
Quick ratio
10.56×
Cash ratio
2.48×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$49.23M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LXRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$11.25M
$692K
$21.1M
$5.34M
$14.18M
$28.87M
$1.26M
$26.47M
Cost of revenue
$79K
$39K
$108K
$201K
$10K
$33K
$30K
$348K
Gross profit
$11.17M
$653K
$20.99M
$5.14M
$14.17M
$28.83M
$1.23M
$26.13M
Selling, general and administrative
$9.46M
$9.75M
$9.23M
$8.76M
$7.6M
$9.35M
$11.61M
$32.26M
Research and development
$16.2M
$17.44M
$12.76M
$11.32M
$18.76M
$15.75M
$15.3M
$26.69M
Total operating expenses
$25.67M
$27.19M
$23.58M
$20.07M
$26.36M
$25.1M
$28.75M
$58.94M
Operating income
-$14.5M
-$26.54M
-$2.59M
-$14.94M
-$12.19M
$3.74M
-$27.51M
-$32.82M
Interest expense
-$1.13M
-$2.61M
$0
-$2.03M
-$2.16M
-$2.32M
$0
-$3.86M
Income before taxes
-$14.01M
-$31.78M
-$1.04M
-$15.53M
-$12.77M
$3.25M
-$25.3M
-$33.77M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$14.01M
-$31.78M
-$1.04M
-$15.53M
-$12.77M
$3.25M
-$25.3M
-$33.77M
Net income attributable to common shareholders
-$14.01M
-$31.78M
-$1.04M
-$15.53M
-$12.77M
$3.25M
-$25.3M
-$33.77M
EBITDA
-$14.4M
-$26.44M
-$2.48M
-$14.82M
-$12.04M
$3.91M
-$27.34M
-$32.69M
Basic earnings per share
-$0.03
-$0.07
$0.00
-$0.04
-$0.04
$0.01
-$0.07
-$0.09
Diluted earnings per share
-$0.03
-$0.07
$0.00
-$0.04
-$0.04
$0.01
-$0.07
-$0.09
Recent news
Company coverage with links to the original publishers.
Lexicon Pharmaceuticals stock surged nearly 6% after analyst Steve Seedhouse from Cantor Fitzgerald initiated coverage with an 'overweight' rating and $8 price target (over 4x the current $1.90 price). Seedhouse highlighted the company's progress on sotagliflozin, an FDA-approved heart failure drug being developed for hypertrophic cardiomyopathy, which works through a different mechanism than competing treatments.
Lexicon Pharmaceuticals announced it will present clinical study data on sotagliflozin for Type 1 diabetes and pilavapadin for diabetic peripheral neuropathic pain at the American Diabetes Association 2026 Scientific Sessions in New Orleans. The company highlighted consistent A1c reductions with sotagliflozin across patient subgroups and pharmacokinetic data for pilavapadin. An NDA resubmission for sotagliflozin in T1D is on track for mid-year 2026.
Hypertrophic cardiomyopathy (HCM) is a complex genetic heart condition causing thickening and stiffening of the heart muscle, leading to symptoms like fatigue, breathlessness, and chest discomfort. The condition can develop at any age and carries risks of serious complications including heart failure and sudden death. While no medications currently prevent HCM, treatments for obstructive HCM may include cardiac myosin inhibitors. Lexicon Pharmaceuticals is conducting the SONATA-HCM clinical trial to investigate sotagliflozin, a potential new treatment that may improve symptoms and reduce heart failure events.
Lexicon Pharmaceuticals announced results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP), supporting the selection of 10mg as the optimal dose for Phase 3 development. The drug achieved nominally significant reduction in average pain at Week 8 versus placebo with good tolerability. Additional preclinical data on spasticity in multiple sclerosis and spinal cord injury models will also be presented at the American Academy of Neurology Annual Meeting.
Lexicon Pharmaceuticals closed a $94.6 million public offering of 32 million common shares at $1.30 per share and a concurrent private placement of 22.4 million common shares and 367,145 Series B convertible preferred shares at $65 per share on February 2, 2026. The company plans to use net proceeds for research and development of drug candidates and general corporate purposes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.